Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D R VanDevanter

Showing results (21-30 of 34) with videos related to

Pageof 4
Sort By:
American Journal of Hematology|July 1, 1996
Unusual expression of mRNA typical of Philadelphia positive acute lymphoblastic leukemia detected in chronic myeloid leukemiaJ A Kirk, J Radich, S Edmands, et al.
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|April 25, 2022
Antipseudomonal treatment decisions during CF exacerbation managementD R VanDevanter, N E West, D B Sanders, et al.
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|December 22, 2021
C-reactive protein (CRP) as a biomarker of pulmonary exacerbation presentation and treatment responseD R VanDevanter, S L Heltshe, M Skalland, et al.
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|August 18, 2020
Changes in symptom scores as a potential clinical endpoint for studies of cystic fibrosis pulmonary exacerbation treatmentD R VanDevanter, S L Heltshe, D B Sanders, et al.
Proceedings of the National Academy of Sciences of the United States of America|June 21, 1994
Pure chromosome-specific PCR libraries from single sorted chromosomesD R VanDevanter, N M Choongkittaworn, K A Dyer, et al.
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|April 26, 2023
Willingness of people with cystic fibrosis receiving elexacaftor/tezacaftor/ivacaftor (ETI) to participate in randomized modulator and inhaled antimicrobial clinical trialsD R VanDevanter, E T Zemanick, M W Konstan, et al.
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|December 3, 2021
Association of site of treatment with clinical outcomes following intravenous antimicrobial treatment of a pulmonary exacerbationD B Sanders, U Khan, S L Heltshe, et al.
Biotechniques|December 1, 1992
Preparation of uniform, intact DNA samples from resected tumor tissues for pulsed-field gel electrophoretic analysesD R VanDevanter, G Yirdaw, C Do, et al.
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|January 28, 2020
Efficacy and safety of ataluren in patients with nonsense-mutation cystic fibrosis not receiving chronic inhaled aminoglycosides: The international, randomized, double-blind, placebo-controlled Ataluren Confirmatory Trial in Cystic Fibrosis (ACT CF)M W Konstan, D R VanDevanter, S M Rowe, et al.
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|January 3, 2018
KB001-A, a novel anti-inflammatory, found to be safe and well-tolerated in cystic fibrosis patients infected with Pseudomonas aeruginosaRaksha Jain, V V Beckett, M W Konstan, et al.
Pageof 4

Showing results (21-30 of 34) with videos related to

Sort By:
Pageof 4
American Journal of Hematology|July 1, 1996
Unusual expression of mRNA typical of Philadelphia positive acute lymphoblastic leukemia detected in chronic myeloid leukemiaJ A Kirk, J Radich, S Edmands, et al.
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|April 25, 2022
Antipseudomonal treatment decisions during CF exacerbation managementD R VanDevanter, N E West, D B Sanders, et al.
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|December 22, 2021
C-reactive protein (CRP) as a biomarker of pulmonary exacerbation presentation and treatment responseD R VanDevanter, S L Heltshe, M Skalland, et al.
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|August 18, 2020
Changes in symptom scores as a potential clinical endpoint for studies of cystic fibrosis pulmonary exacerbation treatmentD R VanDevanter, S L Heltshe, D B Sanders, et al.
Proceedings of the National Academy of Sciences of the United States of America|June 21, 1994
Pure chromosome-specific PCR libraries from single sorted chromosomesD R VanDevanter, N M Choongkittaworn, K A Dyer, et al.
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|April 26, 2023
Willingness of people with cystic fibrosis receiving elexacaftor/tezacaftor/ivacaftor (ETI) to participate in randomized modulator and inhaled antimicrobial clinical trialsD R VanDevanter, E T Zemanick, M W Konstan, et al.
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|December 3, 2021
Association of site of treatment with clinical outcomes following intravenous antimicrobial treatment of a pulmonary exacerbationD B Sanders, U Khan, S L Heltshe, et al.
Biotechniques|December 1, 1992
Preparation of uniform, intact DNA samples from resected tumor tissues for pulsed-field gel electrophoretic analysesD R VanDevanter, G Yirdaw, C Do, et al.
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|January 28, 2020
Efficacy and safety of ataluren in patients with nonsense-mutation cystic fibrosis not receiving chronic inhaled aminoglycosides: The international, randomized, double-blind, placebo-controlled Ataluren Confirmatory Trial in Cystic Fibrosis (ACT CF)M W Konstan, D R VanDevanter, S M Rowe, et al.
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|January 3, 2018
KB001-A, a novel anti-inflammatory, found to be safe and well-tolerated in cystic fibrosis patients infected with Pseudomonas aeruginosaRaksha Jain, V V Beckett, M W Konstan, et al.
Pageof 4